Cargando…
Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen receptor (AR) signaling is the driver of both PCa development and progression and, thus, the major target of current in-use therapies. However, despite the survival benefit of second-generation inhibitors o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019185/ https://www.ncbi.nlm.nih.gov/pubmed/35582011 http://dx.doi.org/10.20517/cdr.2020.54 |